A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.
Partially saturated 1,2,3,4-tetrahydronaphthalene compounds.
Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS.
Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action.
A subclass of G-protein coupled SEROTONIN receptors that couple preferentially to GI-GO G-PROTEINS resulting in decreased intracellular CYCLIC AMP levels.
Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT1 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT1 receptor subtypes.
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS.
An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
A genus of gram-negative, aerobic, rod-shaped bacteria characterized by an outer membrane that contains glycosphingolipids but lacks lipopolysaccharide. They have the ability to degrade a broad range of substituted aromatic compounds.
A serotonin receptor subtype found distributed through the CENTRAL NERVOUS SYSTEM where they are involved in neuroendocrine regulation of ACTH secretion. The fact that this serotonin receptor subtype is particularly sensitive to SEROTONIN RECEPTOR AGONISTS such as BUSPIRONE suggests its role in the modulation of ANXIETY and DEPRESSION.
A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator.
A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
Drugs that bind to but do not activate SEROTONIN 5-HT1 RECEPTORS, thereby blocking the actions of SEROTONIN 5-HT1 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more of the specific 5-HT1 receptor subtypes.
A serotonin receptor antagonist in the CENTRAL NERVOUS SYSTEM used as an antipsychotic.
A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.
Tryptamine substituted with two hydroxyl groups in positions 5 and 7. It is a neurotoxic serotonin analog that destroys serotonergic neurons preferentially and is used in neuropharmacology as a tool.
Collections of small neurons centrally scattered among many fibers from the level of the TROCHLEAR NUCLEUS in the midbrain to the hypoglossal area in the MEDULLA OBLONGATA.
1,4-Diethylene dioxides. Industrial solvents. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), dioxane itself may "reasonably be anticipated to be a carcinogen." (Merck Index, 11th ed)
A psychedelic phenyl isopropylamine derivative, commonly called DOM, whose mood-altering effects and mechanism of action may be similar to those of LSD.
Elimination of ENVIRONMENTAL POLLUTANTS; PESTICIDES and other waste using living organisms, usually involving intervention of environmental or sanitation engineers.
A subtype of dopamine D2 receptors that are highly expressed in the LIMBIC SYSTEM of the brain.
Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics.
Analogs or derivatives of AMPHETAMINE. Many are sympathomimetics and central nervous system stimulators causing excitation, vasopressin, bronchodilation, and to varying degrees, anorexia, analepsis, nasal decongestion, and some smooth muscle relaxation.
Compounds that contain the biogenic monoamine tryptamine and are substituted with one methoxy group and two methyl groups. Members of this group include several potent serotonergic hallucinogens found in several unrelated plants, skins of certain toads, and in mammalian brains. They are possibly involved in the etiology of schizophrenia.
A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
Compounds that specifically inhibit the reuptake of serotonin in the brain.
Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT2 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT2 receptor subtypes.
A genus of asporogenous bacteria that is widely distributed in nature. Its organisms appear as straight to slightly curved rods and are known to be human and animal parasites and pathogens.
The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
Drugs that bind to and activate dopamine receptors.
A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
An ergot derivative that is a congener of LYSERGIC ACID DIETHYLAMIDE. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome.
A genus of asporogenous bacteria isolated from soil that displays a distinctive rod-coccus growth cycle.
A group of compounds consisting in part of two rings sharing one atom (usually a carbon) in common.
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.
A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.
A serotonin receptor subtype found widely distributed in peripheral tissues where it mediates the contractile responses of variety of tissues that contain SMOOTH MUSCLE. Selective 5-HT2A receptor antagonists include KETANSERIN. The 5-HT2A subtype is also located in BASAL GANGLIA and CEREBRAL CORTEX of the BRAIN where it mediates the effects of HALLUCINOGENS such as LSD.
Injections into the cerebral ventricles.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
A bacterial genus of the order ACTINOMYCETALES.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Viruses which lack a complete genome so that they cannot completely replicate or cannot form a protein coat. Some are host-dependent defectives, meaning they can replicate only in cell systems which provide the particular genetic function which they lack. Others, called SATELLITE VIRUSES, are able to replicate only when their genetic defect is complemented by a helper virus.
The measure of the level of heat of a human or animal.
A technique for measuring extracellular concentrations of substances in tissues, usually in vivo, by means of a small probe equipped with a semipermeable membrane. Substances may also be introduced into the extracellular space through the membrane.
A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D2-class receptor genes contain INTRONS, and the receptors inhibit ADENYLYL CYCLASES.
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.
An ester of phthalic acid. It appears as a light-colored, odorless liquid and is used as a plasticizer for many resins and elastomers.
Oxidases that specifically introduce DIOXYGEN-derived oxygen atoms into a variety of organic molecules.
The observable response an animal makes to any situation.
A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain.
Changes in the amounts of various chemicals (neurotransmitters, receptors, enzymes, and other metabolites) specific to the area of the central nervous system contained within the head. These are monitored over time, during sensory stimulation, or under different disease states.
Tests to experimentally measure the tumor-producing/cancer cell-producing potency of an agent by administering the agent (e.g., benzanthracenes) and observing the quantity of tumors or the cell transformation developed over a given period of time. The carcinogenicity value is usually measured as milligrams of agent administered per tumor developed. Though this test differs from the DNA-repair and bacterial microsome MUTAGENICITY TESTS, researchers often attempt to correlate the finding of carcinogenicity values and mutagenicity values.
Liquids that dissolve other substances (solutes), generally solids, without any change in chemical composition, as, water containing sugar. (Grant & Hackh's Chemical Dictionary, 5th ed)
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
In bacteria, a group of metabolically related genes, with a common promoter, whose transcription into a single polycistronic MESSENGER RNA is under the control of an OPERATOR REGION.
The making of a radiograph of an object or tissue by recording on a photographic plate the radiation emitted by radioactive material within the object. (Dorland, 27th ed)
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding.
A phenomenon in which infection by a first virus results in resistance of cells or tissues to infection by a second, unrelated virus.
The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM.
A cylindrical column of tissue that lies within the vertebral canal. It is composed of WHITE MATTER and GRAY MATTER.
The physical activity of a human or an animal as a behavioral phenomenon.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
... di-n-propylamino)-tetralin inhibits food intake in fasted rats by an action at 5-HT1A receptors". Methods and Findings in ... di-n-propylamino)tetralin". European Journal of Pharmacology. 253 (1-2): 53-60. doi:10.1016/0014-2999(94)90756-0. PMID 8013549 ... di-n-propylamino)-tetralin (8-OH DPAT) increase ethanol intake". Psychopharmacology. 115 (1-2): 173-9. doi:10.1007/BF02244769. ... 2C-B 2C-E 2C-T-2 4C-T-2 5-CT 5-MT 5-MeO-DiPT 5-MeO-DMT 5-MeO-MiPT 5-MeO-TMT 6-F-DMT Adatanserin αET Amphetamine[citation needed ...
... di-n-propylamino)-tetralin inhibits food intake in fasted rats by an action at 5-HT1A receptors". Methods and Findings in ... di-n-propylamino)tetralin". European Journal of Pharmacology. 253 (1-2): 53-60. doi:10.1016/0014-2999(94)90756-0. PMID 8013549 ... di-n-propylamino)-tetralin (8-OH DPAT) increase ethanol intake". Psychopharmacology. 115 (1-2): 173-179. doi:10.1007/BF02244769 ... 138 (2): 191-197. doi:10.1016/j.molbrainres.2005.04.009. PMC 5805132. PMID 15921820. Zhang S, Chen H, Zhang C, Yang Y, Popov P ...
... di-n-propylamino)tetralin: a potent and highly stereoselective 5-hydroxytryptamine receptor agonist". Journal of Medicinal ... hydroxy-N,N-di-n-propyl-2-aminotetralin". Proceedings of the National Academy of Sciences of the United States of America. 89 ( ... "7-hydroxy-2-N,N-dipropylaminotetralin - PubChem Public Chemical Database". The PubChem Project. USA: National Center for ... N-dipropyl-7-hydroxy-2-aminotetralin". Naunyn-Schmiedeberg's Archives of Pharmacology. 336 (5): 494-501. doi:10.1007/bf00169305 ...
... di-n-propylamino)tetralin, 5-methoxytryptamine and 5-hydroxytryptamine". Neurosci. Lett. 86 (1): 72-76. doi:10.1016/0304-3940( ... 318 (2-3): 403-409. doi:10.1016/S0014-2999(96)00777-7. PMID 9016931. Craig DA, Eglen RM, Walsh LK, Perkins LA, Whiting RL, ... 323 (2-3): 235-240. doi:10.1016/S0014-2999(97)00029-0. PMID 9128844. Amemiya N, Hatta S, Takemura H, Ohshika H (1996). " ... ISBN 978-1-58829-568-2. S. Nigra / Domenech T, et al., 1997 Cortex / PEROUTKA ET AL., 1989 Cloned / ZGOMBICK JM, ET AL., 1992 ...
... di-n-propylamino) tetralin (8-OH-DPAT) in the rat: site of action and pharmacological analysis". Journal of Cardiovascular ... di-n-propylamino) tetralin (8-OH-DPAT)". Brain Research Bulletin. 15 (4): 377-84. doi:10.1016/0361-9230(85)90005-X. PMID ... di-n-propylamino)tetralin - PubChem Public Chemical Database". The PubChem Project. USA: National Center for Biotechnology ... di-n-propylamino)tetralin". European Journal of Pharmacology. 253 (1-2): 53-60. doi:10.1016/0014-2999(94)90756-0. PMID 8013549 ...
... di-n-propylamino)tetralin MeSH D04.615.638.960.492 - levobunolol MeSH D04.615.638.960.585 - mibefradil MeSH D04.615.638.960.675 ... vitamin k 2 MeSH D04.615.638.721.374.922 - vitamin k 3 MeSH D04.615.638.845 - 1-naphthylamine MeSH D04.615.638.845.800 - ... 8-dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide MeSH D04.615.885.120 - buspirone MeSH D04.615.885.345 - fluorescamine MeSH ... 25-hydroxyvitamin d 2 MeSH D04.808.247.808.489 - fusidic acid MeSH D04.808.247.808.607 - lanosterol MeSH D04.808.247.808.756 - ...
... di-n-propylamino)tetralin in rodents and nonhuman primate". Synapse (New York, N.Y.). 37 (1): 64-70. doi:10.1002/(SICI)1098- ... Karlsson A, Björk L, Pettersson C, Andén NE, Hacksell U (1990). "(R)- and (S)-5-hydroxy-2-(dipropylamino)tetralin (5-OH DPAT): ... dipropylamino)tetralins: conformational and steric parameters of importance for central dopamine receptor activation". Journal ... propyl)amino-5-hydroxytetralin". Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National ...
... di-n-propylamino)tetralin (8-OH-DPAT). Eur J Pharmacol. 1988 Feb 16. 147(1):111-8. [QxMD MEDLINE Link]. ... Cavallaro A, Cavallaro V, Di Vita M, Cappellani A. Main bile duct carcinoma management. Our experience on 38 cases. Ann Ital ... Catena F, Ansaloni L, Di Saverio S, et al. Prospective analysis of 101 consecutive cases of laparoscopic cholecystectomy for ... 8] Circulating immune complexes also have been identified but are unlikely to play a pathogenic role. Circulating T lymphocyte ...
... di-n-propylamino)tetralin (8-OH-DPAT). Eur J Pharmacol. 1988 Feb 16. 147(1):111-8. [QxMD MEDLINE Link]. ... Cavallaro A, Cavallaro V, Di Vita M, Cappellani A. Main bile duct carcinoma management. Our experience on 38 cases. Ann Ital ... Catena F, Ansaloni L, Di Saverio S, et al. Prospective analysis of 101 consecutive cases of laparoscopic cholecystectomy for ... The 2 subtypes are papillary stenosis and sphincter of Oddi dyskinesia. The former is a mechanical problem, and the latter is a ...
... di-n-propylamino)tetralin (8-OH-DPAT). Eur J Pharmacol. 1988 Feb 16. 147(1):111-8. [QxMD MEDLINE Link]. ... Cavallaro A, Cavallaro V, Di Vita M, Cappellani A. Main bile duct carcinoma management. Our experience on 38 cases. Ann Ital ... Catena F, Ansaloni L, Di Saverio S, et al. Prospective analysis of 101 consecutive cases of laparoscopic cholecystectomy for ... 8] Circulating immune complexes also have been identified but are unlikely to play a pathogenic role. Circulating T lymphocyte ...
... di-n-propylamino)tetralin (8-OH-DPAT). Eur J Pharmacol. 1988 Feb 16. 147(1):111-8. [QxMD MEDLINE Link]. ... Cavallaro A, Cavallaro V, Di Vita M, Cappellani A. Main bile duct carcinoma management. Our experience on 38 cases. Ann Ital ... Catena F, Ansaloni L, Di Saverio S, et al. Prospective analysis of 101 consecutive cases of laparoscopic cholecystectomy for ... The 2 subtypes are papillary stenosis and sphincter of Oddi dyskinesia. The former is a mechanical problem, and the latter is a ...
... di-n-propylamino)tetralin (8-OH-DPAT). Eur J Pharmacol. 1988 Feb 16. 147(1):111-8. [QxMD MEDLINE Link]. ... Cavallaro A, Cavallaro V, Di Vita M, Cappellani A. Main bile duct carcinoma management. Our experience on 38 cases. Ann Ital ... Catena F, Ansaloni L, Di Saverio S, et al. Prospective analysis of 101 consecutive cases of laparoscopic cholecystectomy for ... Right upper quadrant ultrasound can detect stones as small as 1-2 mm and has a sensitivity of 95% and a specificity of 97%. The ...
... di-n-propylamino)tetralin (8-OH-DPAT). Eur J Pharmacol. 1988 Feb 16. 147(1):111-8. [QxMD MEDLINE Link]. ... Cavallaro A, Cavallaro V, Di Vita M, Cappellani A. Main bile duct carcinoma management. Our experience on 38 cases. Ann Ital ... Catena F, Ansaloni L, Di Saverio S, et al. Prospective analysis of 101 consecutive cases of laparoscopic cholecystectomy for ... Dig Dis. 1997 Jan-Apr. 15(1-2):23-41. [QxMD MEDLINE Link]. ... Dig Dis Sci. 1994 Feb. 39(2):289-92. [QxMD MEDLINE Link]. ...
... di-n-propylamino)tetralin (8-OH-DPAT). Eur J Pharmacol. 1988 Feb 16. 147(1):111-8. [QxMD MEDLINE Link]. ... Cavallaro A, Cavallaro V, Di Vita M, Cappellani A. Main bile duct carcinoma management. Our experience on 38 cases. Ann Ital ... Catena F, Ansaloni L, Di Saverio S, et al. Prospective analysis of 101 consecutive cases of laparoscopic cholecystectomy for ... Dig Dis. 1997 Jan-Apr. 15(1-2):23-41. [QxMD MEDLINE Link]. ... Dig Dis Sci. 1994 Feb. 39(2):289-92. [QxMD MEDLINE Link]. ...
... di-n-propylamino)tetralin (8-OH-DPAT). Eur J Pharmacol. 1988 Feb 16. 147(1):111-8. [QxMD MEDLINE Link]. ... Cavallaro A, Cavallaro V, Di Vita M, Cappellani A. Main bile duct carcinoma management. Our experience on 38 cases. Ann Ital ... Catena F, Ansaloni L, Di Saverio S, et al. Prospective analysis of 101 consecutive cases of laparoscopic cholecystectomy for ... 8] Circulating immune complexes also have been identified but are unlikely to play a pathogenic role. Circulating T lymphocyte ...
... di-n-propylamino)tetralin (8-OH-DPAT). Eur J Pharmacol. 1988 Feb 16. 147(1):111-8. [QxMD MEDLINE Link]. ... Cavallaro A, Cavallaro V, Di Vita M, Cappellani A. Main bile duct carcinoma management. Our experience on 38 cases. Ann Ital ... Catena F, Ansaloni L, Di Saverio S, et al. Prospective analysis of 101 consecutive cases of laparoscopic cholecystectomy for ... 2] ; the stone clearance rate approaches 100%, the operative mortality rate is less than 1%, the morbidity rate is 2%-5%, and ...
... di-n-propylamino)tetralin (8-OH-DPAT). Eur J Pharmacol. 1988 Feb 16. 147(1):111-8. [QxMD MEDLINE Link]. ... Cavallaro A, Cavallaro V, Di Vita M, Cappellani A. Main bile duct carcinoma management. Our experience on 38 cases. Ann Ital ... Catena F, Ansaloni L, Di Saverio S, et al. Prospective analysis of 101 consecutive cases of laparoscopic cholecystectomy for ... 8] Circulating immune complexes also have been identified but are unlikely to play a pathogenic role. Circulating T lymphocyte ...
... di-n-propylamino)tetralin / metabolism * 8-Hydroxy-2-(di-n-propylamino)tetralin / pharmacology ... 1 Neurobiology 2 Division, Centre de Recherche Pierre Fabre, 17, avenue Jean Moulin, 81106 Castres, France. [email protected] ... F15599 (0.04-2.5) was less disruptive than F13714 (0.005-0.16) or 8-OH-DPAT (0.01-0.63), on basal performance in models of ... To conclude, F15599, in models of memory/cognition, has a more favourable profile than F13714 and 8-OH-DPAT. This suggests that ...
... di-n-propylamino)tetralin), which was characterized as an acting dopamine autoreceptor antagonist with the biochemical and ... Development of a Mass Spectrometric Assay for 5,6,7,9-Tetrahydro-7-Hydroxy-9-Oximidazo [1,2-a]Purine in DNA Modified by 2- ... Stereoselective Synthesis 0f (3S)- and (3R)-3-Hydroxy-3-(2,6-Dimethyl-4-Hydroxyphenyl)Propanoic Acid and its Incorporation into ... This required the development of stereoselective syntheses of (3S)- and (3R)-3-hydroxy-3-(2,6-dimethyl-4-hydroxyphenyl) ...
2) or both (n = 2). Supporting pharmacological experiments demonstrated that the burst firing DRN neurons demonstrated equal ... di-n-propylamino)tetralin, Action Potentials, Adrenergic alpha-Antagonists, Animals, Biotin, Brain Chemistry, Dose-Response ... 2) or both (n = 2). Supporting pharmacological experiments demonstrated that the burst firing DRN neurons demonstrated equal ...
... di-N-propylamino)tetralin to 5-HT1A receptors in Vitro, 2006. *Royal Horticultural Society, Plant Selector: Eschscholzia ... Journal of Natural Products, Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-( ...
... di-n-propylamino)tetralin 94% * Receptor, Serotonin, 5-HT1A 88% ... Effect of a 5-HT 1A receptor agonist (8-OH-DPAT) on the ... Shih, H. J., Fang, S. C., An, L. & Shao, Y. H. J., 2月 1 2020, 於: Prostate. 81, 2, p. 118-126 9 p.. 研究成果: 雜誌貢獻 › 文章 › 同行評審 ... Hsieh, K. L. C., Tsai, R. J., Teng, Y. C. & Lo, C. M., 2月 2017, 於: PLoS ONE. 12, 2, e0171342.. 研究成果: 雜誌貢獻 › 文章 › 同行評審 ... Chang, Y-C., Wang, D-J., Lee, S-Y., Chang, W-C. & Yang, W-C. V., 2008, 於: Journal of Dental Sciences. 3, 1, p. 30-
... di-n-propylamino)tetralin inhibits the reaction [Levodopa results in increased expression of FOS protein]. R ...
... di-N-propylamino)tetralin. 1992 FREO, ULDERICOSONCRANT T. THOLLOWAY H. WGREIG N. HRAPOPORT S. I. + - PSYCHOPHARMACOLOGY - - ... La simulazione può differire dall'esito di un'eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, ... Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina * ... Data di pubblicazione Autori Rivista Serie Titolo libro Time-course of behavioral and regional cerebral metabolic responses to ...
... di-n-propylamino)tetralin, a new centrally acting 5-hydro... J Med Chem. 1981. ... tetralins and related compounds as central 5-h... J Med Chem. 1984. ...
... di-n-propylamino)tetralin (8-OHDPAT): implications for understanding the actions of novel anxiolytics. Cunningham, K. A., ... Kutlar, F., Fei, Y. J., Wilson, J. B., Kutlar, A. & Huisman, T. H. J., 1987, In: Journal of Chromatography A. 394, 2, p. 333- ... Rao, S., Chander, J., Wig, J. D., Yadav, R. V. & Kaushik, S. P., Apr 1987, In: Indian Journal of Gastroenterology. 6, 2, p. 73- ... Myers, J. H., Lamb, F. S. & Webb, R. C., Apr 1987, In: Journal of hypertension. 5, 2, p. 161-171 11 p.. Research output: ...
... di-n-propylamino)tetralin (8-OHDPAT): implications for understanding the actions of novel anxiolytics. Cunningham, K. A., ... May, A. K., Hawkins, M. L., Sharp, K. W. & Mueller, E. W., 2003, In: American Surgeon. 69, 9, p. 755-756 2 p.. Research output ... Ochsner, M. G., Feliciano, D. V., Hawkins, M. L. & Scott Ennis, L., Dec 1 2003, In: American Surgeon. 69, 9, p. 742-743 2 p.. ... Hawkins, M. L., O'Neill, J. A. & Toschlog, E. A., Dec 1 2003, In: American Surgeon. 69, 6, p. 497-498 2 p.. Research output: ...
... di-n-propylamino)tetralin / pharmacology * Analysis of Variance * Animals ... In addition Hom and Het mice were characterized by lower basal body temperature and demonstrated less 8-OH-DPAT-induced ... The possible involvement of raphe nucleus 5-HT1A receptors in these behavioural features was examined by 8-OH-DPAT-induced ...
... di-n-propylamino)tetralin / metabolism * 8-Hydroxy-2-(di-n-propylamino)tetralin / pharmacology ... 1 Neurobiology 2 Division, Centre de Recherche Pierre Fabre, 17, avenue Jean Moulin, 81106 Castres, France. [email protected] ... F15599 (0.04-2.5) was less disruptive than F13714 (0.005-0.16) or 8-OH-DPAT (0.01-0.63), on basal performance in models of ... To conclude, F15599, in models of memory/cognition, has a more favourable profile than F13714 and 8-OH-DPAT. This suggests that ...
... di-n-propylamino)-tetralin inhibits food intake in fasted rats by an action at 5-HT1A receptors". Methods and Findings in ... di-n-propylamino)tetralin". European Journal of Pharmacology. 253 (1-2): 53-60. doi:10.1016/0014-2999(94)90756-0. PMID 8013549 ... di-n-propylamino)-tetralin (8-OH DPAT) increase ethanol intake". Psychopharmacology. 115 (1-2): 173-9. doi:10.1007/BF02244769. ... 2C-B 2C-E 2C-T-2 4C-T-2 5-CT 5-MT 5-MeO-DiPT 5-MeO-DMT 5-MeO-MiPT 5-MeO-TMT 6-F-DMT Adatanserin αET Amphetamine[citation needed ...
... di-n-propylamino)tetralin, a new centrally acting 5-hydro... J Med Chem. 1981. ... tetralins and related compounds as central 5-h... J Med Chem. 1984. ...
... di-n-propylamino)-tetralin hydrobromide (8-OH-DPAT; 5HT-1AR agonist) (187-189) and meta-Chlorophenylpiperazine (mCPP; 5HT2CR ... Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test. Pharmacol Biochem ... Van Grootheest DS, Cath DC, Beekman AT, Boomsma DI. Twin studies on obsessive-compulsive disorder: a review. Twin Res Hum Genet ... Van Grootheest DS, Boomsma DI, Hettema JM, Kendler KS. Heritability of obsessive-compulsive symptom dimensions. Am J Med Genet ...
DI-n-propylamino)tetralin (8-OH-DPAT) A model of presynaptic 5-HT1 function ... 2-methyl-6-nitroquipazine. 3-methyl-6-nitroquipazine. 4-bromo-6-nitroquipazine. 5-bromo-6-nitroquipazine ... Quinoline, 2-(1-piperazinyl)-, Quipazine [Chemical/Ingredient] A piperazine-based nonselective serotonin (5-HT) receptor ... 8-OH-DPAT-induced hyperphagia: Its neural basis and possible therapeutic relevance ...
... di-n-propylamino) tetralin hydrobromide (8-OH-DPAT). This agonist was administered under an Aschoff Type I (CT8) and Aschoff ... Pre-treatment with MDMA significantly attenuated phase shifts to 8-OH-DPAT. We also tested the ability of the clock to phase ... MDMA alters the behavioural response of the Syrian hamster to phase shift to the serotonin 5-HT1A/7 receptor agonist 8-hydroxy- ...
... di-n-propylamino)tetralin (8-OH-DPAT) at 300 nmol, i.th., facilitated reflexes to a median of 144% of pre-drug controls, an ... 2. In a separate set of experiments, 8-OH-DPAT was given at 30 nmol i.th. and potentiated reflexes to a median of 170% of pre- ... 3. After a 3 h recovery period, 8-OH-DPAT was re-administered at 30 nmol, i.th., and increased reflexes to a median value of ... The inability of WAY-100635 to block completely the effects of high doses of 8-OH-DPAT has been noted previously and can be ...
... di-n-propylamino)tetralin 40% * Psychological Generalization 39% * pirenperone 28% ...
... di-N-propylamino) tetralin and haloperidol on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and 5-hydroxyindoleacetic ... Price, D., Mar 2000, In: Drugs. 59, Suppl 1, p. 35-42 8 p.. Research output: Contribution to journal › Review article › peer- ... Morgavi, D. P., Newbold, C. J., Beever, D. E. & Wallace, R. J., Feb 2000, In: Enzyme and Microbial Technology. 26, 2-4, p. 171- ... Smith, P. & Powlson, D. S., 21 Jan 2000, In: Science. 287, 5452, p. 428-429 2 p.. Research output: Contribution to journal › ...
... di-n-propylamino)tetralin 100% * Eating 56% * Temperature 53% ... Food intake, neuroendocrine and temperature effects of 8-OHDPAT ... Klein, E., Patel, J., McDevitt, R. & Zohar, J., 31 Mar 1987, In: Brain Research. 407, 2, p. 312-316 5 p.. Research output: ... Amital, D., Amital, H., Gross, R., Kindler, S. & Zohar, J., 1994, In: British Journal of Psychiatry. 165, OCT., p. 553-554 2 p. ... Aulakh, C. S., Zohar, J., Hill, J. L. & Murphy, D. L., Mar 1991, In: Journal of Psychopharmacology. 5, 2, p. 149-154 6 p.. ...
... di-n-propylamino)tetralin 94% * Receptor, Serotonin, 5-HT1A 88% ... Effect of a 5-HT 1A receptor agonist (8-OH-DPAT) on the ... Shih, H. J., Fang, S. C., An, L. & Shao, Y. H. J., 2月 1 2020, 於: Prostate. 81, 2, p. 118-126 9 p.. 研究成果: 雜誌貢獻 › 文章 › 同行評審 ... Hsieh, K. L. C., Tsai, R. J., Teng, Y. C. & Lo, C. M., 2月 2017, 於: PLoS ONE. 12, 2, e0171342.. 研究成果: 雜誌貢獻 › 文章 › 同行評審 ... Chang, Y-C., Wang, D-J., Lee, S-Y., Chang, W-C. & Yang, W-C. V., 2008, 於: Journal of Dental Sciences. 3, 1, p. 30-
... di-n-propylamino)tetralin (8-OH-DPAT). Eur J Pharmacol. 1988 Feb 16. 147(1):111-8. [QxMD MEDLINE Link]. ... Cavallaro A, Cavallaro V, Di Vita M, Cappellani A. Main bile duct carcinoma management. Our experience on 38 cases. Ann Ital ... Catena F, Ansaloni L, Di Saverio S, et al. Prospective analysis of 101 consecutive cases of laparoscopic cholecystectomy for ... 8] Circulating immune complexes also have been identified but are unlikely to play a pathogenic role. Circulating T lymphocyte ...
Di-N-Propylamino ) tetralin ( 8-OH-DPAT ) read this article I looked for you to list some high. In your brain we tend to get ... di-n-propylamino)tetralin (8-OH-DPAT). The preparation of RNA and oocyte injection have been described elsewhere.10, 16 Briefly ... di-n-propylamino ) tetralin ( )... Reach the receptors the problem causing the boat to sink injected oocytes, no measurable ... 8 Reasons to Try Low-Carb for Mental Health. Prozac (fluoxetine) is an antidepressant and is classified as an SSRI (selective ...
... di-n-propylamino)tetralin inhibits the reaction [Levodopa results in increased expression of FOS protein]. R ...
... di-N-propylamino)tetralin. 1992 FREO, ULDERICOSONCRANT T. THOLLOWAY H. WGREIG N. HRAPOPORT S. I. + - PSYCHOPHARMACOLOGY - - ... La simulazione può differire dallesito di uneventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, ... Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina * ... Data di pubblicazione Autori Rivista Serie Titolo libro Time-course of behavioral and regional cerebral metabolic responses to ...
... di-N-propylamino)tetralin to 5-HT1A receptors in Vitro, 2006. *Royal Horticultural Society, Plant Selector: Eschscholzia ... Journal of Natural Products, Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-( ...
2) or both (n = 2). Supporting pharmacological experiments demonstrated that the burst firing DRN neurons demonstrated equal ... di-n-propylamino)tetralin, Action Potentials, Adrenergic alpha-Antagonists, Animals, Biotin, Brain Chemistry, Dose-Response ... 2) or both (n = 2). Supporting pharmacological experiments demonstrated that the burst firing DRN neurons demonstrated equal ...
... di-n-propylamino)tetralin (8-OHDPAT): implications for understanding the actions of novel anxiolytics., Eur. J. Pharmacol. ... Sugimoto et al., 2003, Involvement of 5-HT(2) receptor in imipramine-induced hyperglycemia in mice., Horm. Metab. Res. ... Kimura et al., 1991, Dual activation by lisuride of central serotonin 5-HT(1A) and dopamine D(2) receptor sites: drug ... Bang-Andersen et al., 2011, Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal ...
... di-n-propylamino)tetralin), which was characterized as an acting dopamine autoreceptor antagonist with the biochemical and ... Development of a Mass Spectrometric Assay for 5,6,7,9-Tetrahydro-7-Hydroxy-9-Oximidazo [1,2-a]Purine in DNA Modified by 2- ... Stereoselective Synthesis 0f (3S)- and (3R)-3-Hydroxy-3-(2,6-Dimethyl-4-Hydroxyphenyl)Propanoic Acid and its Incorporation into ... This required the development of stereoselective syntheses of (3S)- and (3R)-3-hydroxy-3-(2,6-dimethyl-4-hydroxyphenyl) ...
... di-n-propylamino)tetralin, a new centrally acting 5-hydro... J Med Chem. 1981. ...
... di-n-propylamino)tetralin; 5-HT, 5-hydroxytryptamine; CGP54626, [S-(R*,R*)]-[3-[[1-(3,4-Dichlorophenyl)ethyl]amino]-2- ... α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid [AMPA], kainate, NMDA; for the human 5-HT receptors 5-HT1B, 5-HT1D [rat], ... di-n-propylamino)tetralin; WAY 100635, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- N-(2-pyridyl)cyclohexanecarboxamide. ... Andrianov VV, Gainutdinov KHL, Gainutdinova TKH, Mukhamedshina DI, Shtark MB. Membranotropic effects of antibodies to S100 ...
... di-n-propylamino)tetralin results in increased expression of IL6 protein]. CTD. PMID:30366073. NCBI chr 4:5,214,602...5,219,178 ... di-n-propylamino)tetralin results in increased expression of HTR1A protein]. CTD. PMID:30366073. NCBI chr 2:36,694,174... ... di-n-propylamino)tetralin results in increased expression of IFNG protein]. CTD. PMID:30366073. NCBI chr 7:53,903,339... ... di-n-propylamino)tetralin results in increased expression of AIF1 protein]. CTD. PMID:30366073. NCBI chr20:3,646,784... ...
... di-n-propylamino)tetralin (8-OH-DPAT). Eur J Pharmacol. 1988 Feb 16. 147(1):111-8. [QxMD MEDLINE Link]. ... Cavallaro A, Cavallaro V, Di Vita M, Cappellani A. Main bile duct carcinoma management. Our experience on 38 cases. Ann Ital ... Catena F, Ansaloni L, Di Saverio S, et al. Prospective analysis of 101 consecutive cases of laparoscopic cholecystectomy for ... 8] Circulating immune complexes also have been identified but are unlikely to play a pathogenic role. Circulating T lymphocyte ...
... di-n-propylamino) tetralin hydrobromide (8-OH-DPAT). This agonist was administered under an Aschoff Type I (CT8) and Aschoff ... Pre-treatment with MDMA significantly attenuated phase shifts to 8-OH-DPAT. We also tested the ability of the clock to phase ... MDMA alters the behavioural response of the Syrian hamster to phase shift to the serotonin 5-HT1A/7 receptor agonist 8-hydroxy- ...
... di-n-propylamino)tetralin (8-OHDPAT): implications for understanding the actions of novel anxiolytics. Cunningham, K. A., ... Kutlar, F., Fei, Y. J., Wilson, J. B., Kutlar, A. & Huisman, T. H. J., 1987, In: Journal of Chromatography A. 394, 2, p. 333- ... Rao, S., Chander, J., Wig, J. D., Yadav, R. V. & Kaushik, S. P., Apr 1987, In: Indian Journal of Gastroenterology. 6, 2, p. 73- ... Myers, J. H., Lamb, F. S. & Webb, R. C., Apr 1987, In: Journal of hypertension. 5, 2, p. 161-171 11 p.. Research output: ...
... di-n-propylamino)tetralin ([3H]8-OH-DPAT) to 5-HT(1A) receptors was selectively increased by 20% on average (p ,0.05) in the ... hydroxy-2-(di-n-propylamino)tetralin ([3H]8-OH-DPAT) to 5-HT(1A) receptors was selectively increased by 20% on average (p ,0.05 ... di-n-propylamino)tetralin ([3H]8-OH-DPAT) to 5-HT(1A) receptors was selectively increased by 20% on average (p ,0.05) in the ... di-n-propylamino)tetralin ([3H]8-OH-DPAT) to 5-HT(1A) receptors was selectively increased by 20% on average (p ,0.05) in the ...
... di-n-propylamino) tetralin (8-OH-DPAT) in domestic goats (Capra aegagrus hircus). Pfitzer, S., Woodward, A. P., Laubscher, L., ... Douglas, L., Jackson, D., Woods, C. & Usher, K., Oct 2019, In: Mental Health Practice. 22, 6, p. 21-27 8 p.. Research output: ... Gregor, S., Beavan, G., Culbert, A., John, P. K., Ngo, N. V., Keating, B., Sun, R. & Radwan, I., 2 Oct 2019, In: International ... Nanayakkara, B. S., OBrien, C. L. & Gordon, D. M., 1 Dec 2019, In: Environmental Microbiology Reports. 11, 6, p. 817-824 8 p. ...
Initiation and intensification were examined by comparing neurotoxic effects of a high-dose (10 mg/kg × 3 at 2 h intervals) ... with a low-dose (2 mg/kg × 3) under controlled-environmental conditions. Initiation of a serotonin syndrome was estimated by ... elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats. Eur J Pharmacol. 2008;588:198-206. ... 8b; TpH2+), FG-containing (FG+), and TpH2/FG-containing neurons (FG+/TpH2+). Except for the HD-H+ group, changes in Tcor in the ...
... di-N-propylamino) tetralin in rats. J Pharmacol Exp Ther. 2006;316:830-4. [PubMed] 81. Stafford SA, Coote JH. Activation of D2- ... receptor agonist 7-hydroxy-2-(di-N-propylamino)tetralin in anesthetized rats. Neuroscience. 2007;145:605-10. [PubMed] 85. ... Larsson K, van Dis H. Seminal discharge following intracranial electrical stimulation. Brain Res. 1970;23:381-6. [PubMed] 63. ... 1988;2:37-41.. 28. Levin R. Revisiting post-ejaculatory refractory time-what we know and what we do not know in males and ...
... di-n-propylamino)tetralin (0.5 and 2.5 micrograms) into the dorsal raphe nucleus caused a dose-related fall in hippocampal ... Electrical stimulation (1-ms pulse width, 300 microA, 2-20 Hz) of the dorsal raphe nucleus for 20 min caused a rapid rise in ... di-n-propylamino)tetralin (0.5 and 2.5 micrograms) into the dorsal raphe nucleus caused a dose-related fall in hippocampal ... di-n-propylamino)tetralin, Anesthesia, Animals, Dialysis, Electric Stimulation, Extracellular Space, Hippocampus, ...
... propylamino)tetralin hydrochloride (1S,2R)-tranylcypromine hydrochloride + ... 5-hydroxy-6-methoxy-2-methylchromone-7-O-rutinoside 5-hydroxy-7-prop-2-en-(E)-ylidene-7,7a-dihydro- 2H-cyclopenta[b]pyran-6-one ... 1S,6R-di(2-)methylbutanoyloxy-4S-hydroxy-8S-benzoyloxy-9R-(3-)furancarbonyloxy-13-acetyloxy-beta-dihydroagarofuran ... 3beta,16alpha)-16-hydroxy-13,28-epoxyoleanan-3-yl alpha-L-Rhap-(1->2)-beta-D-Glcp-(1->4)-[beta-D-Glcp-(1->2)]-alpha-L- ...
Microinjection of the preferential dopamine receptor D3 agonist 7-hydroxy-n,n-di-n-propylaminotetralin hydrobromide into the ... di-N-propylamino)tetralin in anesthetized rats. ...
  • The possible involvement of raphe nucleus 5-HT1A receptors in these behavioural features was examined by 8-OH-DPAT-induced hypothermia. (nih.gov)
  • dose of 8-OH-DPAT is selective for 5-HT1A receptors in this preparation. (wikigenes.org)
  • Blockage of muscle acetylcholine receptors by the serotonin 1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). (croatianfranciscans.org)
  • In addition Hom and Het mice were characterized by lower basal body temperature and demonstrated less 8-OH-DPAT-induced hypothermia than WT mice. (nih.gov)
  • F13714 (0.04 mg/kg) a chemical congener of F15599, and 8-OH-DPAT (0.01 or 0.16), were inactive against these phencyclidine-induced deficits, and/or even worsened basal performances. (nih.gov)
  • F15599 (0.04-2.5) was less disruptive than F13714 (0.005-0.16) or 8-OH-DPAT (0.01-0.63), on basal performance in models of attention (5-choice serial reaction time task) and working memory (delayed non-matching to position). (nih.gov)
  • 2. In a separate set of experiments, 8-OH-DPAT was given at 30 nmol i.th. (wikigenes.org)
  • and complete reversal of the effects of 8-OH-DPAT at a cumulative dose of 5.5 nmol. (wikigenes.org)
  • Dose- and time-dependent effects of 1(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) on local cerebral glucose metabolism in awake rats. (unipd.it)
  • and potentiated reflexes to a median of 170% of pre-drug levels (n = 8). (wikigenes.org)
  • Behavioral and cerebral metabolic effects of the 5-HT1A agonists buspirone and 8-OH-DPAT. (unipd.it)
  • This study investigated whether repeated exposure to the serotonin neurotoxin MDMA alters the behavioural response of the Syrian hamster to phase shift to the serotonin 5-HT1A/7 receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin hydrobromide (8-OH-DPAT). (erowid.org)
  • Injection of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (0.5 and 2.5 micrograms) into the dorsal raphe nucleus caused a dose-related fall in hippocampal output of 5-HT compared to saline-injected controls. (ox.ac.uk)
  • Ejaculation induced by i.c.v. injection of the preferential dopamine D(3) receptor agonist 7-hydroxy-2-(di-N-propylamino)tetralin in anesthetized rats. (pelvipharm.com)
  • Other behavioral abnormalities such as forepaw treading, hind limb abduction, and Straub tail, which typically occur in the syndrome caused by 5-hydrotryptophan in combination with a monoamine oxidase inhibitor [ 7 , 8 ], are relatively rare in the MDMA-elicited serotonin syndrome. (biomedcentral.com)
  • The current (dose)-dependent inhibition produced by the serotonin agonists did not differ significantly from the inhibition produced by MDMA except for the 5-HT1A agonist 8-hydroxy-(2-di-n-propylamino) tetralin, which inhibited glutamate-evoked firing significantly more than MDMA or any of the other serotonin agonists. (erowid.org)
  • Preweanling (postnatal day 17-18) Sprague-Dawley rat pups were tested in both the absence and presence of milk following administration of various doses of the 5-HT1A agonists 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) or ipsapirone, the 5-HT1B agonist 1-(3-chlorophenyl)piperazine (mCPP) or the 5-HT2 agonist 1-(2,5-dimethoxy-4-iodo-phenyl)-2-aminopropane (DOI). (erowid.org)
  • The same maximal drop in body temperature (~2.5°C) was elicited by all three agonists, 8-OH-DPAT being the most potent (EC 50 = 0.05 mg/kg), followed by gepirone (1.8 mg/kg) and (+) S-20499 (8 mg/kg). (uthscsa.edu)
  • D-fenfluramine 12.5 mg/kg×8, 14 days prior to testing) on behavioural (5-HT syndrome) and neuroendocrine [prolactin and adrenocorticotrophin (ACTH)] responses in rats to acute administration of D-fenfluramine and other serotonergic agonists. (ox.ac.uk)
  • For comparison, the effect of pCA pre-treatment on the behavioural responses to acute administration of pCA and the 5-HT(1A) and 5-HT(2) receptor agonists 8-hydroxy-2-(di- n- propylamino)tetralin (8-OH-DPAT) and 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), respectively, were also examined. (ox.ac.uk)
  • It has been previously shown that 5-hydroxy-(l), 6-hydroxy- (2) and 'I-hydroxy-2-(di-n-propylamino)-tetralin (3) exhibit considerable dopamine (DA) receptor stimulating activity.31~I n this series, the 5-hydroxy isomer 1 is the most active compound, being a highly active central DA-receptor agonist. (erowid.org)
  • The present study investigated the effects a lower ambient or core body temperature would have on damage to striatal dopamine (DA) neurons produced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). (nih.gov)
  • Using in vivo microdialysis, vilazodone (10 mg/kg p.o.) was demonstrated to cause a 2-fold increase in extracellular 5-HT but no change in noradrenaline or dopamine levels in frontal cortex of freely moving rats. (nih.gov)
  • paroxetine, 3 mg/kg p.o.), produced no increase in cortical 5-HT whilst increasing noradrenaline and dopamine 2 and 4 fold, respectively. (nih.gov)
  • We are currently investigating the pharmacological properties of 2-aminotetralins and related compounds using biochemical and behavioral methods recently published. (erowid.org)
  • We systematically examined the behavioral phenotypes of three OCD mouse models induced by pharmacological reagents [RU24969, 8-hydroxy-DPAT hydrobromide (8-OH-DPAT), and 1-(3-chlorophenyl) piperazine hydrochloride-99% (MCPP)], and compared the activated brain regions in each model, respectively. (biomedcentral.com)
  • 1993). Serotonergic lesions decrease m- and d-opiate receptor binding in discrete areas of the hypothalamus and in the midbrain central gray: Brain Research Vol 625(2) Oct 1993, 269-275. (fandom.com)
  • 8-OH-DPAT decreased mouthing while ipsapirone, mCPP and DOI had no effect upon this behavior. (erowid.org)
  • Both 8-OH-DPAT and mCPP produced alterations in limb positioning, with 8-OH-DPAT administration resulting in a poor control of the hindlimbs and mCPP inducing a hindlimb straddle position. (erowid.org)
  • RU24969, 8-OH-DPAT, or MCPP administration caused specific OCD-like behaviors. (biomedcentral.com)
  • We exposed neonatal rats to daily doses of diazinon or parathion on postnatal days (PND)1-4 and evaluated 5HT receptors and the 5HT transporter in brainstem and forebrain on PND5, focusing on doses of each agent below the maximum tolerated dose and spanning the threshold for cholinesterase inhibition: 0.5, 1, or 2 mg/kg for diazinon, and 0.02, 0.05, and 0.1 mg/kg for parathion. (nih.gov)
  • WAY 100135 competitively antagonized the forepaw treading caused by 8-OH-DPAT in reserpine-pretreated rats. (uthscsa.edu)
  • 1990). Enhanced spatial discrimination learning in rats following 5,7-DHT-induced serotonergic deafferentation of the hippocampus: Brain Research Vol 518(1-2) Jun 1990, 61-66. (fandom.com)
  • Immobilization stress in rats: Effect on rectal temperature and possible role of brain monoamines in hypothermia: Psychopharmacology Vol 73(2) Apr 1981, 157-160. (fandom.com)
  • 5,7-Dihydroxytryptamine-induced mouse killing and behavioral reversal with ventricular administration of serotonin in rats: Behavioral & Neural Biology Vol 30(2) Oct 1980, 178-190. (fandom.com)
  • Mice received systemic MPTP treatment at two different temperatures, 4 degrees C and 22 degrees C. MPTP-treated mice maintained at 4 degrees C demonstrated (1) a greater hypothermic response, (2) a significant reduction in striatal DA content and tyrosine hydroxylase (TH) activity, and (3) significantly greater striatal 1-methyl-4-phenylpyridinium (MPP+) levels, as compared to mice dosed with MPTP at room temperature. (nih.gov)
  • The effects of MDL 73005EF (8-[2-(2,3-dihydro-1,4-benzodioxin-2-yl)methylamino]-8- azaspiro[4,5]decan-7,9-dione methyl sulphonate), a novel selective 5-HT1A receptor ligand with putative anxiolytic properties, were explored using models of central pre- and postsynaptic 5-HT1A receptor function in the male rat. (ncl.ac.uk)
  • Diazinon evoked up-regulation of 5HT 1A and 5HT 2 receptor expression even at doses devoid of effects on cholinesterase activity, a pattern similar to that seen earlier for another organophosphate, chlorpyrifos. (nih.gov)
  • by contrast, (+) S-20499, at doses up to 75 mg/kg, did not attenuate the forepaw treading induced by either 8-OH-DPAT or 5-MeODMT. (uthscsa.edu)
  • In contrast to 8-OH-DPAT, MDL 73005EF significantly increased plasma prolactin but apparently not through a 5-HT receptor-mediated mechanism. (ncl.ac.uk)
  • An aromatic ketone that is 1-phenylethanone substituted by a hydroxy group at position 4 and a methoxy group at position 3. (mcw.edu)
  • In reserpine-pretreated animals, 8-OH-DPAT (maximal effect at 2-4 mg/kg) and 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) (5 mg/kg) induced forepaw treading, whereas gepirone (10 mg/kg) and (+) S-20499 (75 mg/kg) did not. (uthscsa.edu)
  • 8-OH-DPAT-treated mice exhibited excessive spray-induced grooming as well as impairments in recognition memory. (biomedcentral.com)
  • Concurrent administration of MK-801 or 8-OHDPAT increased the striatal MPP+ levels following MPTP treatment. (nih.gov)
  • pCA pre-treatment attenuated all components of the behavioural response to pCA but had little or no effect on the behavioural responses to 8-OH-DPAT or DOI, suggesting that there was no alteration in post-synaptic 5-HT(1A) or 5-HT(2) receptor function. (ox.ac.uk)
  • A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. (lookformedical.com)
  • Brain Research Vol 693(1-2) Sep 1995, 70-79. (fandom.com)
  • An analysis of neuronal elements within the median nucleus of the raphe that mediate lesion-induced increases in locomotor activity: Brain Research Vol 268(2) Jun 1983, 211-223. (fandom.com)
  • These data identify a previously unrecognized role of 5-HT neurons in the CO 2 chemoreflex, whereby they enhance the response of the rest of the respiratory network to CO 2 . (jneurosci.org)
  • 5-HT1A receptor binding was assayed in post-mortem prefrontal cortex using [3H]8-OH-DPAT, and specific binding determined by 1 microM 5-HT. (nih.gov)
  • MDL 73005EF failed to alter basal plasma adrenocorticotropin (ACTH) levels but, in common with pindolol, attenuated the ACTH response to the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). (ncl.ac.uk)
  • Unlike adults, in the social realities intercourse was reported in excess an average length of 3.1 inches , but he never felt safe in patients using iui , often using iui-ready prepa- with di is approx- choice). (eagfwc.org)
  • The prevalence of OCD is ~ 2.3% in the population [ 1 ], and most of the patients develop symptoms before 35 years old [ 2 ]. (biomedcentral.com)